奥浦迈(688293) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was CNY 67,917,690.55, representing a decrease of 6.53% compared to the same period last year[5]. - The net profit attributable to shareholders was CNY 24,191,151.59, down by 4.26% year-on-year[5]. - The net profit after deducting non-recurring gains and losses was CNY 21,054,676.90, reflecting an 11.50% decline compared to the previous year[5]. - In Q1 2023, the total revenue was CNY 67,917,690.55, a decrease of 6.5% compared to CNY 72,665,072.90 in Q1 2022[25]. - The net profit for Q1 2023 was CNY 24,065,980.32, compared to CNY 25,268,632.49 in Q1 2022, indicating a decline of 4.8%[25]. - The net profit attributable to the parent company for Q1 2023 is CNY 24,191,151.59, a decrease of 4.3% compared to CNY 25,268,632.49 in Q1 2022[26]. - The basic and diluted earnings per share for Q1 2023 are CNY 0.30, down from CNY 0.41 in Q1 2022, representing a decline of 26.8%[26]. Cash Flow - The net cash flow from operating activities increased significantly by 90.86%, amounting to CNY 4,496,312.41[5]. - Cash inflow from operating activities for Q1 2023 is CNY 64,579,092.78, an increase of 21.0% from CNY 53,366,977.29 in Q1 2022[28]. - The net cash flow from operating activities for Q1 2023 is CNY 4,496,312.41, up from CNY 2,355,851.35 in Q1 2022, indicating a growth of 90.9%[28]. - Cash outflow from investing activities in Q1 2023 is CNY 361,891,423.70, significantly higher than CNY 25,022,935.96 in Q1 2022[29]. - The net cash flow from investing activities for Q1 2023 is -CNY 90,260,145.10, compared to -CNY 24,322,935.96 in Q1 2022, reflecting a deterioration in investment cash flow[29]. - The net cash flow from financing activities for Q1 2023 is -CNY 3,123,849.50, an improvement from -CNY 5,992,187.60 in Q1 2022[29]. - The total cash and cash equivalents at the end of Q1 2023 is CNY 1,416,319,230.30, compared to CNY 275,189,112.45 at the end of Q1 2022, showing a substantial increase[29]. - The company's cash and cash equivalents decreased to CNY 1,416,319,230.30 as of March 31, 2023, from CNY 1,505,906,562.65 at the end of 2022, a drop of 5.9%[21]. Research and Development - Research and development expenses totaled CNY 9,727,974.76, an increase of 81.11%, accounting for 14.32% of operating revenue, which is an increase of 6.93 percentage points[5]. - The company's R&D investment totaled 9.73 million RMB, accounting for 14.32% of revenue, representing an increase of 81.11% year-over-year[17]. - R&D expenses increased to CNY 9,727,974.76 in Q1 2023, up from CNY 5,371,286.68 in Q1 2022, representing an increase of 80.5%[25]. - As of the end of Q1 2023, the company had 125 confirmed drug development pipelines using its cell culture products, an increase of 14 from the end of 2022[17]. - Among the 125 pipelines, 72 are in the preclinical stage, 25 in Phase I, 10 in Phase II, 17 in Phase III, and 1 in commercial production[18]. Operational Efficiency - The company has strengthened internal management and improved operational efficiency in response to challenges in the biopharmaceutical industry[16]. - The gross profit margin remained high, improving by approximately 1 percentage point compared to the same period last year[16]. - The revenue from cell culture media significantly increased, demonstrating strong resilience in the high-end culture media sector[16]. - The company signed a strategic research cooperation agreement with East China University of Science and Technology in November 2022, establishing a joint research institute[17]. - The company plans to expand its market presence and has resumed some projects that were previously delayed due to adverse market conditions[19]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,352,102,249.90, a slight increase of 0.19% from the end of the previous year[5]. - The total assets as of March 31, 2023, were CNY 2,352,102,249.90, slightly up from CNY 2,347,749,143.04 at the end of 2022[22]. - The company's total liabilities decreased to CNY 142,562,885.63 as of March 31, 2023, from CNY 163,071,138.95 at the end of 2022, a reduction of 12.5%[23]. - The company reported an increase in accounts receivable to CNY 77,863,525.60 as of March 31, 2023, compared to CNY 75,869,111.97 at the end of 2022, an increase of 2.6%[21]. - The company reported a significant increase in accounts receivable by 126.35%, primarily due to an increase in bank acceptance bills received[8]. Strategic Developments - The company is currently constructing a CDMO biopharmaceutical commercialization production platform, expected to enhance service capabilities significantly upon completion in H1 2023[19]. - The company's major IVD clients had temporarily increased their procurement of culture media in Q1 2022, which affected the year-over-year comparison[16]. - The company did not execute any mergers or acquisitions during the reporting period[26]. - The actual controllers of the company hold a combined 31.49% of the shares, with 24.41% directly held by the main shareholder[14].